stockportfolio.pro
ImmunityBio, Inc. (IBRX)
Healthcare · Biotechnology · NasdaqGS
ImmunityBio, Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $44,000 | $45,000 | $47,000 | $2.20M | $605,000 | $934,000 | $240,000 | $622,000 | $14.74M | $113.29M |
| Gross profit | — | — | — | — | — | — | $240,000 | $622,000 | $14.74M | $112.53M |
| Net income | $-120.81M | $-96.42M | $-96.23M | $-157.78M | $-221.85M | $-346.79M | $-416.57M | $-583.20M | $-413.56M | $-351.40M |
| Net margin | -274565.9% | -214273.3% | -204736.2% | -7165.2% | -36669.6% | -37129.6% | -173569.6% | -93761.4% | -2804.8% | -310.2% |
Source: ImmunityBio, Inc. SEC filings (10-K). 13 years of history available in the interactive view.
Explore 13 years of ImmunityBio, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track IBRX in your portfolio →
ImmunityBio, Inc. financial history by metric
About ImmunityBio, Inc.
ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead biologic product candidate includes Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors; and 3M-052, a synthetic TLR7/8 agonist and 3M-052 formulations and related technology. The company has collaboration agreements with National Cancer Institute; Serum Institute of India Private Limited; and BeOne Medicines Ltd. It has license agreement with 3M Innovative Properties Company and Access to Advanced Health Institute. ImmunityBio, Inc. is based in San Diego, California.
ImmunityBio, Inc. — frequently asked questions
What is ImmunityBio, Inc.'s revenue?
ImmunityBio, Inc. (IBRX) reported revenue of $113.29M for fiscal year 2025, up 668.3% from the prior year, according to its SEC filings.
Is ImmunityBio, Inc. profitable?
No — IBRX reported a net loss of $-351.40M in fiscal 2025.
What is IBRX's P/E ratio?
ImmunityBio, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is ImmunityBio, Inc. growing?
IBRX's revenue grew at roughly 184.8% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does ImmunityBio, Inc. have?
As of fiscal year 2025, IBRX carried roughly $478.84M in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is ImmunityBio, Inc.'s gross margin?
IBRX's gross margin was 99.3% in fiscal 2025 — gross profit of $112.53M on revenue of $113.29M.
What is ImmunityBio, Inc.'s market cap?
ImmunityBio, Inc. (IBRX) has a market capitalization of about $7.47B, based on the latest data in our nightly-refreshed cache.
When does ImmunityBio, Inc.'s fiscal year end?
IBRX's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from ImmunityBio, Inc.'s official SEC filings (10-K and 10-Q), covering 13 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.